203 related articles for article (PubMed ID: 6427019)
1. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
3. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
Lemay A; Quesnel G
Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.
Lemay A; Maheux R; Huot C; Blanchet J; Faure N
Am J Obstet Gynecol; 1988 Feb; 158(2):233-6. PubMed ID: 3124618
[TBL] [Abstract][Full Text] [Related]
5. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
Masaoka K; Kitazawa M; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
[TBL] [Abstract][Full Text] [Related]
6. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
Baumann R; Kuhl H; Taubert HD; Sandow J
Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
[TBL] [Abstract][Full Text] [Related]
7. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
Bergquist C; Nillius SJ; Wide L; Lindgren A
Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
[TBL] [Abstract][Full Text] [Related]
8. Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase.
Lemay A; Sandow J; Bureau M; Maheux R; Fontaine JY; Mérat P
Fertil Steril; 1988 Mar; 49(3):410-7. PubMed ID: 3125068
[TBL] [Abstract][Full Text] [Related]
9. Effect of LHRH agonist (buserelin) on pulsatile secretion of LHRH and LH.
Okuda K; Ushiroyama T; Yoshikawa M; Sugimoto O
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1889-93. PubMed ID: 3145318
[TBL] [Abstract][Full Text] [Related]
10. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
Takeuchi H; Kobori H; Kikuchi I; Sato Y; Mitsuhashi N
J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.
Lemay A; Metha AE; Tolis G; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1983 May; 39(5):668-73. PubMed ID: 6404661
[TBL] [Abstract][Full Text] [Related]
13. Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens.
Shaw RW; Matta W
Clin Reprod Fertil; 1986 Oct; 4(5):329-36. PubMed ID: 3100012
[TBL] [Abstract][Full Text] [Related]
14. Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?
Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; von der Ohe M; Nevinny-Stickel J
Contraception; 1981 Feb; 23(2):187-95. PubMed ID: 6786826
[TBL] [Abstract][Full Text] [Related]
15. Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis.
Fraser HM; Sandow J; Cowen GM; Lumsden MA; Haining R; Smith SK
Fertil Steril; 1990 Jan; 53(1):61-8. PubMed ID: 2104808
[TBL] [Abstract][Full Text] [Related]
16. Sustained gonadal suppression in fertile women with the LHRH agonist buserelin.
Hardt W; Schmidt-Gollwitzer M
Clin Endocrinol (Oxf); 1983 Nov; 19(5):613-7. PubMed ID: 6416718
[TBL] [Abstract][Full Text] [Related]
17. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with a LH-RH-agonist: a new contraceptive method?
Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J
Acta Eur Fertil; 1981 Sep; 12(3):275-6. PubMed ID: 6803498
[TBL] [Abstract][Full Text] [Related]
19. [Ovarian suppression by the GnRH analog buserelin in the treatment of endometriosis. Clinical, biochemical and pelviscopic studies].
Raitz von Frentz M; Schweppe KW
Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):634-9. PubMed ID: 2145192
[TBL] [Abstract][Full Text] [Related]
20. Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinizing hormone-releasing hormone agonist at different days after the midcycle luteinizing hormone surge.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1983 May; 39(5):661-7. PubMed ID: 6404660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
